Antioxidants and Sperm Quality: What the Cochrane Review Found

Antioxidant supplements for male fertility are among the most heavily marketed products in this field, and there is a genuine biological rationale behind them. There is also a large Cochrane systematic review, updated in 2022, which is the best available summary.

Its scope:

• 90 randomized controlled trials
• 10,303 subfertile men, aged 18 to 65, part of couples attending a fertility clinic
• 20 different oral antioxidants compared and combined
• Live birth as the primary outcome, with clinical pregnancy, adverse events and sperm parameters as secondary outcomes

The headline result: antioxidants may lead to increased live birth rates, with an odds ratio of 1.43 (95% CI 1.07 to 1.91). Expressed in absolute terms, if the chance of live birth without treatment is assumed to be 16%, the estimated chance with antioxidants is between 17% and 27%.

That sounds encouraging until the certainty rating is read alongside it. The review graded this evidence as very low certainty.

The certainty rating is not a formality. It reflects specific, identifiable problems with the underlying trials.

What limited the evidence:

• Of 67 studies in the meta-analysis, only 20 reported clinical pregnancy, and only 12 reported live birth at all
• The live birth finding rested on just 246 live births among 1,283 couples
• The contributing trials were small or medium-sized
• Several were at high risk of bias

The most important analysis in the whole review is the sensitivity analysis. When studies at high risk of bias were removed, there was no evidence of increased live birth — Peto OR 1.22, 95% confidence interval 0.85 to 1.75, across 8 trials and 827 men, P = 0.27. The confidence interval crosses 1, meaning no effect is entirely consistent with the data.

In plain terms: the apparent benefit was driven substantially by the least reliable trials. That is exactly the pattern seen when a real effect is absent and weak study design produces a false positive — though it does not prove the effect is absent, only that the evidence cannot establish it.

Clinical pregnancy showed a larger apparent effect, OR 1.89 (95% CI 1.45 to 2.47), graded low certainty — better than very low, but still based on 327 pregnancies across 20 small studies.

The reasoning behind these products is sound, which is part of why they are so widely sold.

Sperm are unusually vulnerable to oxidative damage:

• Their membranes are rich in polyunsaturated fatty acids, which oxidise readily
• They carry very little cytoplasm, so they have limited internal antioxidant defense
• They cannot repair DNA damage once mature
• Reactive oxygen species damage the membrane, impair motility, and fragment DNA

Oxidative stress is estimated to contribute to a substantial share of male subfertility. So supplying antioxidants to counter it is a coherent idea.

Two things complicate it. First, some reactive oxygen species are required for normal sperm function, including capacitation and fertilization — so excessive supplementation is not necessarily better, and the concept of reductive stress from over-supplementation has been raised.

Second, a plausible mechanism is not evidence of benefit. Many interventions with excellent rationale fail when tested properly, which is why the trial evidence matters more than the biology.

A balanced reading, neither dismissing nor overselling:

Reasons it may still be reasonable to try:

• Adverse effects were minimal, and no difference in miscarriage rate was found between antioxidant and placebo groups
• Cost is low compared with fertility treatment
• The possibility of benefit has not been excluded — very low certainty means uncertain, not disproven

Reasons for caution:

• The live birth benefit does not survive removing poor-quality trials
• Most supplements are unregulated for content, dose and purity, so what is on the label may not be what is in the capsule
• Higher doses are not established as better, and may not be harmless
• Money and time spent here may delay investigation of a specific, treatable cause

If you do take one:

• Give it about three months before retesting, since sperm take roughly 74 days to develop
• Use a product that discloses its composition and doses
• Tell your clinician, particularly if you take other medication
• Treat it as an adjunct, not as a reason to postpone a workup

If reducing oxidative stress is the goal, several interventions act on that pathway directly and rest on firmer ground than supplementation.

• Stopping smoking — a direct and substantial source of oxidative stress
• Reducing alcohol intake
• Addressing obesity, which drives oxidative stress, raises scrotal temperature, and disrupts the hormonal axis
• Treating varicocele where clinically indicated, which is itself associated with raised oxidative stress
• Treating genital tract infection, which raises white cells and reactive oxygen species in semen
• Reducing sustained heat exposure
• Reviewing medications that affect sperm production, especially testosterone and anabolic steroids

These are less convenient than a daily capsule, which is precisely why supplements are attractive. They also address causes rather than adding a counterweight to an ongoing insult.

Investigation matters more than either. A varicocele, an obstruction, a hormonal problem or testosterone use will not respond to antioxidants, and identifying one changes the treatment entirely.

A distinction that gets lost in most summaries: the effect on sperm parameters and the effect on having a baby are different questions, and the evidence differs for each.

Many trials report improvements in measured sperm parameters — concentration, motility, morphology, DNA fragmentation. These are the results most often quoted in product marketing, and they are the easiest outcomes to measure.

The problem is that parameters are surrogate outcomes:

• A semen analysis measures the sample, not the ability to fertilize an egg
• Improvements within or near the normal range may have no bearing on conception
• Live birth is the outcome that matters, and it is the one with the weakest evidence

This is why the Cochrane review made live birth its primary outcome, and why the certainty rating there is the number to read. Of the 67 studies in the meta-analysis, only 12 reported live birth at all.

When you see a supplement advertised on the strength of improved motility or reduced DNA fragmentation, that claim may well be accurate about the trial it cites. It is not the same as evidence that taking it makes a baby more likely.

If you decide to try one, the products vary enormously and most are not regulated in the way medicines are.

What to look for:

• Full disclosure of every ingredient with its dose, not a 'proprietary blend' that hides quantities
• Doses you can compare against those used in published trials
• A manufacturer that states testing and quality standards
• An expiry date and batch number

What to treat sceptically:

• Claims to 'boost fertility' or 'increase sperm count' stated as fact
• Very long ingredient lists at token doses, which look comprehensive and deliver little
• Testimonials in place of trial data
• Any product presented as an alternative to medical investigation

Tell your clinician what you are taking. Some ingredients interact with medication, and high-dose single-nutrient products are not automatically harmless simply because they are sold without prescription.

• Ayurveda and Fertility: What Has Actually Been Tested
• Can Stress Cause Infertility? What the Evidence Actually Shows
• PGT-A in IVF: What the Evidence Shows About Testing Embryos